Evidence map›Paper›PMID 37196186›Full record

ArticleEpigenetics2023

Multiomics analysis of adaptation to repeated DNA damage in prostate cancer cells.

D Challis, T Lippis, R Wilson, E Wilkinson, J Dickinson, A Black, I Azimi, A Holloway, P Taberlay, K Brettingham-Moore

Open access · diamondAbstract read
In one paragraph

Article in Epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

D ChallisTasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
T LippisTasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
R WilsonCentral Science Laboratory, University of Tasmania, Hobart, Tasmania, Australia.
E WilkinsonMenzies Institute of Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
J DickinsonMenzies Institute of Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
A BlackMedical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
I AzimiSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia.
A HollowayTasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
P TaberlayTasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
K Brettingham-MooreTasmanian School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.ORCID 0000-0002-4304-4586
University of Tasmania · AURoyal Hobart Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA damage is frequently utilized as the basis for cancer therapies; however, resistance to DNA damage remains one of the biggest challenges for successful treatment outcomes. Critically, the molecular drivers behind resistance are poorly understood. To address this question, we created an isogenic model of prostate cancer exhibiting more aggressive characteristics to better understand the molecular signatures associated with resistance and metastasis. 22Rv1 cells were repeatedly exposed to DNA damage daily for 6 weeks, similar to patient treatment regimes. Using Illumina Methylation EPIC arrays and RNA-seq, we compared DNA methylation and transcriptional profiles between the parental 22Rv1 cell line and the lineage exposed to prolonged DNA damage. Here we show that repeated DNA damage drives the molecular evolution of cancer cells to a more aggressive phenotype and identify molecular candidates behind this process. Total DNA methylation was increased while RNA-seq demonstrated these cells had dysregulated expression of genes involved in metabolism and the unfolded protein response (UPR) with Asparagine synthetase (ASNS) identified as central to this process. Despite the limited overlap between RNA-seq and DNA methylation, oxoglutarate dehydrogenase-like (OGDHL) was identified as altered in both data sets. Utilising a second approach we profiled the proteome in 22Rv1 cells following a single dose of radiotherapy. This analysis also highlighted the UPR in response to DNA damage. Together, these analyses identified dysregulation of metabolism and the UPR and identified ASNS and OGDHL as candidates for resistance to DNA damage. This work provides critical insight into molecular changes which underpin treatment resistance and metastasis.

Indexed as

DNA MethylationProstatic NeoplasmsCell Line, TumorDNA DamageHumansMaleMultiomicsDNA damageDNA methylationProstate cancerProteometranscriptome

Identifiers

PMID37196186
PMCPMC10193866
OpenAlexW4376958697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.